## IQV: IQVIA Holdings Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 0.1% below STRENGTH zone (3.0-6.0%). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($217.63)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 3
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. Pacer Advisors Inc. Sells 299,354 Shares of IQVIA Holdings Inc. $IQV**
- Source: MarketBeat | 20251226T120613 | Somewhat-Bullish | Relevance: 100%
- Pacer Advisors Inc. significantly reduced its stake in IQVIA Holdings Inc. (NYSE:IQV) by 29.1% during the third quarter, selling 299,354 shares and now owning 728,498 shares valued at $138.37 million. This move comes as other institutional investors have either boosted or initiated positions in the medical research company. IQVIA recently reported strong third-quarter earnings, beating analyst estimates, and currently holds a "Moderate Buy" rating from analysts with an average target price of $243.19.

**2. IQVIA Holdings (NYSE:IQV) Has A Pretty Healthy Balance Sheet**
- Source: 富途牛牛 | 20251224T180913 | Neutral | Relevance: 100%
- IQVIA Holdings Inc. (NYSE:IQV) is analyzed for its debt levels relative to its balance sheet health. The company has a significant debt of US$15.0 billion, which reduces to US$13.0 billion net debt after accounting for cash reserves. While its debt-to-EBITDA ratio is 4.5 and EBIT covers interest expense 3.4 times, suggesting manageability, its total liabilities significantly exceed its cash and near-term receivables, leading to a cautious outlook on its debt levels despite its strong free cash flow generation.

**3. Vontobel Holding Ltd. Raises Stock Holdings in IQVIA Holdings Inc. $IQV**
- Source: MarketBeat | 20251224T142700 | Bullish | Relevance: 100%
- Vontobel Holding Ltd. significantly increased its stake in IQVIA Holdings Inc. (NYSE:IQV) by 909.1% in the third quarter, now owning 550,430 shares valued at approximately $104.55 million. The medical research company has received positive analyst sentiment, with a "Moderate Buy" consensus rating and an average price target of $243.19. IQVIA exceeded Q3 earnings expectations and provided strong FY2025 guidance, trading with a market cap of $38.3 billion.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-02 | Morgan Stanley | $265 | $250 | +6% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-02 | Morgan Stanley | main | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 5 ($1.46M) |
| Sells | 2 ($4.59M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 46.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Vanguard Group Inc: 11.4% (-0.9%)
- Blackrock Inc.: 8.7% (+4.5%)
- Harris Associates L.: 6.7% (-3.1%)
- State Street Corpora: 4.4% (-1.0%)
- JPMORGAN CHASE & CO: 3.9% (+110.0%)

### Key Risks

1. Insider selling cluster: $4.6M in recent transactions.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.96 indicates undervaluation relative to growth. Analyst sentiment positive (1 raises, avg +6%). Insider selling cluster ($4.6M in 90 days), potential headwind. Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $38.6B |
| Beta | 1.37 |
| 52W Range | $134.65 - $234.30 |
| Short Interest | 3.2% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.96 |
| Forward P/E | 17.5 |
| Current P/E | 19.1 |
| YoY Growth | 8.8% |
| EPS Direction | STABLE |

### Technicals

MRS_10 improving modestly (+0.9% over 5 days). Below STRENGTH zone by 2.9pp (needs >3.0% for momentum thesis). MRS_5 at 0.6% confirms short-term momentum alignment. Full SMA alignment bullish (above 20/50/200 SMAs). RSI neutral at 58. OFD pattern: +MTL (Rally).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | 0.06% (CS: 75) | Neutral |
| RSI_14 | 57.8 | Neutral |
| MACD Histogram | -0.14 | Bearish |
| vs SMA20 | 1.011x | Above |
| vs SMA50 | 1.030x | Above |
| vs SMA200 | 1.240x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $226.83
- **Stop Loss:** $217.63 (4.1% risk)
- **Target:** $236.03 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 143
- **Position Value:** $32,436.69
- **Portfolio %:** 32.44%
- **Risk Dollars:** $1,320.00
- **Risk Per Trade:** 1.32%
- **Modifiers:** L1 110% | L2 120% | Combined 1.32x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.10x |
| L2 Sector | TREND (Zone A) | 1.20x |

*NORMAL regime with selective risk appetite amid holiday trading. VIX at extreme lows (13.6) signals complacency while positive yield curve (+59bps) and stable economic data support continuation. Focus on quality names with AI/infrastructure exposure while monitoring January volatility reset.*

### Earnings

**Next:** 2026-02-05 (Est: $3.40)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.98 | $3.00 | +0.8% |
| 2025Q2 | $2.77 | $2.81 | +1.4% |
| 2025Q1 | $2.63 | $2.70 | +2.6% |
| 2024Q4 | $3.11 | $3.12 | +0.4% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_10*